InsiderDB
Sign inStart free trial
Committee overlap: HELP

Sen. Alan Armstrong bought Cardinal Health (CAH)

Sen. Alan Armstrong (R-OK) · $1K–$15K · traded Mar 27, 2026

Why this is a committee overlap

Armstrong is a member of the Senate Committee on Health, Education, Labor, and Pensions, which oversees the Healthcare sector. Cardinal Health is classified in the Medical - Distribution industry.

An overlap is a fact about the trade, not evidence of wrongdoing. Committee assignments are current ones.

Transaction
Bought
Amount
$1K–$15K
Owner
The member
Traded
Mar 27, 2026
Disclosed
Jul 21, 2026
Days to disclose
116 (after the 45-day deadline)
Asset type
Stock
As filed
Cardinal Health, Inc. Common Stock
Industry
Medical - Distribution · Healthcare
Official filing ↗All of Armstrong's tradesAll Congress trades in CAH

Other trades in this filing

All of Armstrong's trades →

Recent Congress trades in CAH

Company context for CAH

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. CAHLobbying report·Lobbying disclosures

    CAH: third_quarter 2026 lobbying report

    Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation. Issues related to tariffs, trade, and U.S. trade policy. Issues related to Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS), competitive bidding, and reimbursement to home healthcare agencies. Issues related to drug pricing, bona fide service fees, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine, pharmacy services administrative organizations; Issues related to prov

    Public: Oct 20, 2026, 1:54 PM EDTOriginal source ↗
  2. CAHLobbying report·Lobbying disclosures

    CAH: third_quarter 2026 lobbying report

    General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. Pharmaceutical tariffs Supply chain issues affecting the pharmaceutical industry

    Public: Oct 16, 2026, 3:29 PM EDTOriginal source ↗
  3. CAHLobbying report·Lobbying disclosures

    CAH: second_quarter 2026 lobbying report

    Issues related to drug pricing, bona fide service fees, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine, and pharmacy services administrative organizations; Issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages; Issues related to Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS), competitive bidding, reimbursement to home healthcare agencies, and acute hospital care at home services; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5031/S. 3159, Preservin

    Public: Jul 20, 2026, 10:07 AM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.